Compare TMDX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | LGND |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2019 | N/A |
| Metric | TMDX | LGND |
|---|---|---|
| Price | $67.93 | $219.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $148.22 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 1.2M | 192.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $605,494,000.00 | N/A |
| Revenue This Year | $24.25 | $1.25 |
| Revenue Next Year | $18.75 | $19.41 |
| P/E Ratio | $362.75 | ★ $76.27 |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $70.00 | $98.90 |
| 52 Week High | $156.00 | $247.38 |
| Indicator | TMDX | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 19.80 | 48.98 |
| Support Level | N/A | $180.85 |
| Resistance Level | $131.86 | $227.92 |
| Average True Range (ATR) | 5.31 | 10.66 |
| MACD | -3.88 | -2.19 |
| Stochastic Oscillator | 0.17 | 42.22 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.